Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breastcancer. Already approved in ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breastcancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Some results have been hidden because they may be inaccessible to you